Item Details

Prescription Drugs: Implications of Drug Labeling and Off-Label Use : Statement of Sarah F. Jagger, Director of Health Services Quality and Public Health Issues, Health, Education, and Human Services Division, Before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives

United States General Accounting Office
Format
EBook; Book; Government Document; Online
Published
Washington, D.C. : The Office ; Gaithersburg, MD (P.O. Box 6015, Gaithersburg 20884-6015) : The Office [distributor, 1996]
Language
English
Variant Title
Implications of drug labeling and off-label use
Series
Testimony
SuDoc Number
GA 1.5/2:T-HEHS-96-212
Description
8 p. ; 28 cm.
Notes
  • Not distributed to depository libraries in a physical form.
  • "September 12, 1996."
  • Includes bibliographical references.
Series Statement
Testimony ; GAO/T-HEHS-96-212
Other Forms
Available via Internet from the GPO Access web site. Address as of 5/21/2001: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi ?dbname=gao&docid=f:he96212t.pdf; current access is available via PURL.
Logo for Copyright Not EvaluatedCopyright Not Evaluated
Technical Details
  • Access in Virgo Classic

  • LEADER 02283nam a2200421 a 4500
    001 u3736053
    003 SIRSI
    005 20010525150027.0
    008 961001s1996 dcu b f000 0 eng d
    035
      
      
    a| (Sirsi) ocm35662123
    035
      
      
    a| (OCoLC)35662123
    037
      
      
    a| 157458 b| GAO (202) 512-6000 (Voice); (202) 512-6061 (Fax) f| paper copy
    040
      
      
    a| GAO c| GAO d| OCL d| GPO d| DLC d| MvI
    043
      
      
    a| n-us---
    074
      
      
    a| 0546-D-01 (online)
    086
    0
      
    a| GA 1.5/2:T-HEHS-96-212
    090
      
      
    a| RS59.U54 b| J33
    100
    1
      
    a| Jagger, Sarah F.
    245
    1
    0
    a| Prescription drugs : b| implications of drug labeling and off-label use : statement of Sarah F. Jagger, Director of Health Services Quality and Public Health Issues, Health, Education, and Human Services Division, before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives / c| United States General Accounting Office.
    246
    3
    0
    a| Implications of drug labeling and off-label use
    260
      
      
    a| Washington, D.C. : b| The Office ; a| Gaithersburg, MD (P.O. Box 6015, Gaithersburg 20884-6015) : b| The Office [distributor, c| 1996]
    300
      
      
    a| 8 p. ; c| 28 cm.
    440
      
    0
    a| Testimony ; v| GAO/T-HEHS-96-212
    500
      
      
    a| Not distributed to depository libraries in a physical form.
    500
      
      
    a| "September 12, 1996."
    504
      
      
    a| Includes bibliographical references.
    530
      
      
    a| Available via Internet from the GPO Access web site. Address as of 5/21/2001: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi ?dbname=gao&docid=f:he96212t.pdf; current access is available via PURL.
    596
      
      
    a| 1
    650
      
    0
    a| Drugs x| Labeling z| United States.
    650
      
    0
    a| Drugs x| Prescribing z| United States.
    650
      
    0
    a| Drugs z| United States x| Generic substitution.
    650
      
    0
    a| Generic drugs z| United States.
    710
    1
      
    a| United States. b| General Accounting Office.
    710
    1
      
    a| United States. b| Congress. b| House. b| Committee on Government Reform and Oversight. b| Subcommittee on Human Resources and Intergovernmental Relations.
    856
    4
    1
    u| http://purl.access.gpo.gov/GPO/LPS12207 z| Adobe Acrobat Reader required
    999
      
      
    a| GA 1.5/2:T-HEHS-96-212 w| SUDOC i| 3736053-1001 l| INTERNET m| UVA-LIB t| INTERNET

Availability

Google Preview

Read Online